Article 7

GLP-1 Medications for Women Over 40: Hormones, Menopause, and Weight Loss

Women over 40 often find that losing weight becomes dramatically harder than it was in their 30s. The culprit is usually hormonal — specifically, the perimenopause and menopause transition that shifts fat distribution, slows metabolism, disrupts sleep, and can make even the most disciplined diet and exercise efforts feel frustratingly ineffective.

GLP-1 medications like semaglutide and tirzepatide are now being used by a growing number of women in this demographic, and many report that these drugs finally give them results that diet and exercise alone couldn’t deliver. But the interaction between GLP-1 therapy and the hormonal changes of midlife is nuanced — and important to understand.

Why Weight Loss Gets Harder After 40

The physiological challenges facing women over 40 are real and well-documented:

Declining Estrogen

Estrogen plays a role in regulating where the body stores fat. As estrogen declines during perimenopause (typically ages 40–52), fat distribution shifts from the hips and thighs (subcutaneous fat) to the abdomen (visceral fat). Visceral fat is metabolically more dangerous — it’s strongly linked to insulin resistance, cardiovascular disease, and type 2 diabetes.

Declining Progesterone

Falling progesterone levels contribute to water retention, sleep disruption, and mood changes that can trigger stress eating and reduced exercise motivation.

Testosterone Decline

Women also have testosterone (in smaller amounts than men), and it plays an important role in muscle maintenance. As testosterone declines in midlife, sarcopenia (muscle loss) accelerates — lowering metabolic rate and making fat loss harder.

Insulin Resistance

The hormonal changes of menopause directly increase insulin resistance. Many women who never had blood sugar issues develop prediabetes in their 40s and 50s without significant lifestyle changes. This metabolic shift makes weight harder to manage and fat storage more efficient.

Disrupted Sleep

Hot flashes, night sweats, and progesterone-related sleep disruption are common in perimenopause. Poor sleep dysregulates hunger hormones (ghrelin, leptin, and cortisol), driving increased appetite and cravings for calorie-dense foods.

How GLP-1 Medications Address Midlife Weight Challenges

GLP-1 medications work through mechanisms that directly counter several of the weight-promoting effects of menopause:

• Appetite suppression: They reduce hunger signals regardless of hormonal status, making it easier to maintain a caloric deficit even when estrogen-driven fat storage tendencies are strong.
• Blood sugar regulation: By improving insulin secretion and sensitivity, GLP-1 drugs counteract the insulin resistance that accelerates during menopause.
• Reduced visceral fat: GLP-1 therapy is particularly effective at reducing visceral abdominal fat — the very type that accumulates disproportionately during menopause. This reduces cardiovascular and metabolic risk.
• Reduced food noise: Many women report that constant preoccupation with food is dramatically reduced on GLP-1 therapy, making it easier to focus on building healthy habits rather than fighting constant hunger.

What Clinical Evidence Exists for Women Over 40?

The major GLP-1 weight loss trials (STEP trials for semaglutide, SURMOUNT trials for tirzepatide) enrolled large proportions of women and included participants in the 40–65 age range. Subgroup analyses have generally shown that women respond similarly to men in terms of weight loss, with some studies suggesting slightly better outcomes for women.

Specifically relevant: the SURMOUNT-1 trial of tirzepatide reported that postmenopausal women achieved similar weight loss to premenopausal women, with tirzepatide 15mg producing an average 21.4% body weight reduction over 72 weeks regardless of menopausal status.

GLP-1 and Hormone Replacement Therapy (HRT)

Many women over 40 considering GLP-1 therapy are also using or considering hormone replacement therapy (HRT) for menopause symptom management. The good news is that there are no known direct interactions between GLP-1 medications and HRT (estrogen + progesterone combinations), and the two therapies can generally be used together.

Some researchers suggest that HRT may actually enhance GLP-1 outcomes by addressing some of the hormonal headwinds that make weight loss harder in menopause. Estrogen therapy has been shown to reduce visceral fat accumulation and improve insulin sensitivity — effects that complement rather than compete with GLP-1 mechanisms.

If you’re considering or already using HRT, discuss this with both your gynecologist and your GLP-1 prescriber so all providers are aware of your full regimen.

Bone Health: A Critical Consideration

Rapid weight loss — regardless of cause — can reduce bone mineral density. This is particularly concerning for women over 40, who are already at elevated risk for osteopenia and osteoporosis due to declining estrogen. GLP-1-mediated weight loss adds an additional consideration to bone health management.

Key steps to protect your bones while on GLP-1 therapy:

• Weight-bearing exercise: Resistance training and weight-bearing cardio (walking, hiking, dancing) stimulate bone formation. This is non-negotiable for women over 40 on GLP-1 therapy.
• Adequate calcium and vitamin D: Aim for 1,200mg of calcium daily (from food and supplements combined) and 800–2,000 IU of vitamin D3. Discuss with your provider.
• DEXA scan: If you haven’t had a baseline bone density scan and you’re over 45 or in menopause, ask your provider about getting one.
• HRT consideration: Estrogen therapy is protective for bone. For women who are both in menopause and on GLP-1 therapy, HRT may provide important bone protection benefits.

Managing Side Effects as a Woman Over 40

GI side effects (nausea, reflux, constipation) are the most common complaints with GLP-1 medications. Menopausal women may find that fluctuating estrogen levels affect GI motility, potentially making constipation (already a common concern) more pronounced. Staying well hydrated, eating adequate fiber, and remaining physically active are important mitigation strategies.

Setting Realistic Expectations

GLP-1 medications can be extremely effective for women over 40 — but hormonal factors mean results may come a bit more slowly than in younger women or men. Don’t compare your progress to clinical trial averages, which include diverse populations. Focus on your own trend: consistent, steady progress over 3–6 months is a success.

Also remember that weight loss in women over 40 often changes body composition more than the scale reflects. Many women lose fat while simultaneously building some muscle (especially with resistance training), which may show as slower scale progress but better fitting clothes and improved strength.

The Bottom Line

For women over 40 facing the metabolic challenges of perimenopause and menopause, GLP-1 medications offer powerful reinforcement for weight loss goals that hormonal changes have made increasingly difficult. The drugs directly address insulin resistance, visceral fat accumulation, and appetite dysregulation — the core mechanisms driving midlife weight gain.

Combined with appropriate exercise, adequate protein, attention to bone health, and a conversation with your provider about HRT if appropriate, GLP-1 therapy can help women in this age group achieve and maintain meaningful weight loss for the first time in years.